Israeli startup Biomica today announced a $20 million financing round led by Shanghai Healthcare Capital (SHC). Biomica plans to use the new funding to further develop its pipeline of microbiome-based therapeutics. The human Microbiome, genetic material of all the microbes that live on and inside the human body. Biomica is a clinical-stage biopharmaceutical company developing therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. It is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), from which it licenses a dedicated Computational Predictive Biology platform (CPB).